Moomoo AIのまとめ
On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there...Show More
On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there is no intention to participate in any transaction with such a purpose or effect. The statement was duly signed by David Kroin, who serves as the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and as a Director for Deep Track Biotechnology Master Fund, Ltd.
2024年2月2日、Deep Track Capital、LP、Deep Track Biotechnology Master Fund、Ltd.、およびDavid KroinはInvivyd、Inc.の重要なステークを報告しました。SECに提出されたスケジュール13Gによると、グループは合わせて9,000,000株のInvivydの普通株式を所有しており、これは同社の証券クラスの7.56％を占めています。13d-1（c）ルールに基づく申請書によると、株式は共同で投票および決定権を持って保有されています。Deep Track CapitalとDavid Kroinの本社はグリニッジ、CTにあり...すべて展開
2024年2月2日、Deep Track Capital、LP、Deep Track Biotechnology Master Fund、Ltd.、およびDavid KroinはInvivyd、Inc.の重要なステークを報告しました。SECに提出されたスケジュール13Gによると、グループは合わせて9,000,000株のInvivydの普通株式を所有しており、これは同社の証券クラスの7.56％を占めています。13d-1（c）ルールに基づく申請書によると、株式は共同で投票および決定権を持って保有されています。Deep Track CapitalとDavid Kroinの本社はグリニッジ、CTにあり、Deep Track Biotechnology Master Fundの本社はケイマン諸島にあります。この申請によれば、株式はInvivyd、Inc.の支配を変更または影響する目的で取得されたものではなく、その目的または影響を持つ取引に参加する意図はありません。この声明は、Deep Track Capital、LPの投資顧問の一般パートナーの取締役およびDeep Track Biotechnology Master Fund、Ltd.のディレクターを務めるDavid Kroinによって正式に署名されました。
役に立った
役に立たない
